Keunchil Park
Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.
Overview
Keunchil Park is a thoracic medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Journal of Clinical Oncology report of the CHRYSALIS study, which showed that the EGFR-MET bispecific antibody amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy, the basis of the drug's first approval. He has led many EGFR-directed lung cancer trials in Asia.
Similar pages
not linked directly; found by shared links- PersonAlice T. Shaw
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonGregory J. Riely
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonPaul K. Paik
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
- PersonMatthew D. Hellmann
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
- PersonRobert C. Doebele
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonMyung-Ju Ahn
Shares Samsung Medical Center, Non-small-cell lung cancer and the tag lung.
- PersonFerdinandos Skoulidis
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- PersonMartin Reck
Shares Non-small-cell lung cancer and the tags lung, trialist.